[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Next Article in Journal
Improving Skin Carotenoid Levels in Young Students through Brief Dietary Education Using the Veggie Meter
Next Article in Special Issue
Cordyceps militaris—Fruiting Bodies, Mycelium, and Supplements: Valuable Component of Daily Diet
Previous Article in Journal
Renal Ischemia/Reperfusion Mitigation via Geraniol: The Role of Nrf-2/HO-1/NQO-1 and TLR2,4/MYD88/NFκB Pathway
Previous Article in Special Issue
Comparative Assessment of the Antioxidant and Anticancer Activities of Plicosepalus acacia and Plicosepalus curviflorus: Metabolomic Profiling and In Silico Studies
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 11
Issue 8
10.3390/antiox11081569
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antioxidant and Anti-Inflammatory Activity of Five Medicinal Mushrooms of the Genus Pleurotus

by
Jan Stastny
1,
Petr Marsik
1,
Jan Tauchen
1,
Matej Bozik
1,
Anna Mascellani
1,
Jaroslav Havlik
1,
Premysl Landa
2,
Ivan Jablonsky
3,
Jakub Treml
4,
Petra Herczogova
4,
Roman Bleha
5,
Andriy Synytsya
5 and
Pavel Kloucek
1,*
1
Department of Food Science, Faculty of Agrobiology, Food and Natural Resources, The Czech University of Life Sciences Prague, Kamýcká 129, 165 21 Prague, Czech Republic
2
Laboratory of Plant Biotechnologies, Institute of Experimental Botany of the Czech Academy of Sciences, Rozvojová 313, 165 02 Prague, Czech Republic
3
Department of Horticulture, Faculty of Agrobiology, Food and Natural Resources, The Czech University of Life Sciences Prague, Kamýcká 129, 165 21 Prague, Czech Republic
4
Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Palackého Třída 1946/1, 612 00 Brno, Czech Republic
5
Department of Carbohydrates and Cereals, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Technická 5, 166 28 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
Antioxidants 2022, 11(8), 1569; https://doi.org/10.3390/antiox11081569
Submission received: 7 July 2022 / Revised: 9 August 2022 / Accepted: 10 August 2022 / Published: 13 August 2022
(This article belongs to the Special Issue Culinary-Medicinal Mushrooms and Plants: Organic Compounds and Bioactive Substances with Antioxidant Activity)
Versions Notes

Abstract

:
Within the group of higher fungi, edible medicinal mushrooms have a long history of being used as food and in folk medicine. These species contain biologically active substances with many potential beneficial effects on human health. The Pleurotus genus is representative of medicinal mushrooms because Pleurotus ostreatus is one of the most commonly cultivated culinary mushrooms. In our study, we focused on lesser-known species in the genus Pleurotus and measured their antioxidant and anti-inflammatory activity. We prepared extracts of the mushrooms and analyzed them using HPLC−HRMS, GC−MS, and 1H-NMR. Significant differences in biological activities were found among the Pleurotus spp. extracts. A MeOH extract of P. flabellatus was the most active as a radical scavenger with the highest ORAC, while a chloroform extract had significant anti-inflammatory COX-2 activity. The 80% MeOH extract of P. flabellatus contained the highest amounts of ergosterol, ergothioneine, and mannitol. The 80% MeOH extract of P. ostreatus Florida was the most active in the NF-κB inhibition assay and had the highest content of β-glucans (43.3% by dry weight). Given the antioxidant and anti-inflammatory properties of P. flabellatus, the potential therapeutic usefulness of this species is worth evaluating through in-depth investigations and confirmation by clinical trials.

1. Introduction

Edible mushrooms have been a significant part of human culture since ancient times [1] and those with medicinal properties have had a long tradition in the treatment of various human diseases [2]. In addition to their high content of micro and macronutrients [1], mushrooms also produce a wide array of secondary metabolites including biologically active compounds [2]. Out of the approximately 14,000 known mushroom species, about 700 are considered pharmacologically active [3]. Some of these mushroom species are consumed directly or are employed as food supplements and functional foods [4]. In view of their remarkable usefulness as both a food and a medicine, the new term, ‘mushroom nutraceutical’, was introduced to describe these edible medicinal mushrooms [5].
The genus Pleurotus includes types of edible, wood-decaying mushroom. Various Pleurotus species have been employed throughout history in medicine [6]; for example, they have bene used to strengthen joints, tendons, and muscles, improve cardiovascular health [7], and stimulate the immune system. Currently, there are 207 classified species in the genus Pleurotus [8]. The oyster mushroom, P. ostreatus (Fr.) P. Kumm, is one of the most economically significant species [9] and the second most important commercially cultivated mushroom [10]. It has been proven in numerous studies that P. ostreatus offers many health-promoting benefits such as anticancer, antioxidant, antitumor, antiviral, antibacterial, antidiabetic, and anti-hypercholesteremic activities. One of the most studied biological effects is the modulation of the immune system response, which involves different anti-inflammatory mechanisms [11]. There are several other Pleurotus species that are less common in the edible mushroom growing industry [12], but still possess some bioactive properties. The pink oyster mushroom (P. flabellatus) and the Indian oyster mushroom (P. pulmonarius) were reported to have antioxidant, anti-inflammatory, and antimicrobial activities as well [13,14,15,16,17,18,19,20,21,22,23,24].
The fruiting body of P. ostreatus contains approximately one hundred different compounds [9], including polysaccharide-proteins, polysaccharide-peptides, proteoglycans, functional proteins, and polysaccharides [25]. Specific proteoglycans from P. ostreatus have been found to have anticancer, immunomodulatory [26], and antioxidant activity [27]. The mushroom cell walls are rich in non-starch polysaccharides, of which β-D-glucans are the most interesting functional components [9] because they are the most common natural macrophage activators [26]. The α- and β-glucans and high molecular weight polysaccharides were reported to increase the production of cytokines by dendritic cells, activate natural killer cells, and increase the production of macrophages [11]. Besides the well-studied β-D-glucans, P. ostreatus contains other compounds, e.g., phenolic compounds like protocatechuic acid, gallic acid, homogentisic acid, rutin, myricetin, chrysin, naringin, α- and γ-tocopherol, ascorbic acid, β-carotene [9], cinnamic acid, p-hydroxybenzoic acid [28], and ergothioneine, many of which are potent antioxidants abundant in P. ostreatus; these are also found in other Pleurotus species [29].
Some other species or varieties of Pleurotus that are less frequently employed in the mushroom cultivation industry and have not been covered by local legislation differ in content and type of bioactive metabolites but may contain novel compounds not found in the commercially cultivated varieties of P. ostreatus [30]. Therefore, based on these facts, this study focused on the exploration of the less common species and varieties of the Pleurotus genus. Our major assumption was that because the various species and varieties of the genus differ extensively in the type and abundance of their constituents, they are likely to possess some novel biological activities.

2. Materials and Methods

2.1. Materials

2.1.1. Samples and Cultivation

The following species and varieties were chosen from the collection of the Research Institute of Crop Production in Prague: P. flabellatus 5013, P. pulmonarius KZ50, P. opuntiae 5012, P. ostreatus Sylvan Ivory, and P. ostreatus 5175 Florida. Pleurotus spp. mushrooms were cultivated and harvested by the Department of Horticulture at CZU Prague on wheat straw pellets substrate. Two thousand five hundred g of substrate was pasteurized (90 °C for 24 h), moistened with water (67–69% humidity), and placed in polypropylene bags. Three percent grain spawn from selected Pleurotus samples was added into the cooled substrate. The samples were mixed thoroughly with the substrate and cultivated at 24 °C for 21 days. The samples were then switched to 17 °C in a relative humidity of 85–90% and a light of 1000 lux for the next 21 days and then harvested.

2.1.2. Sample Preparation

The harvested mushrooms were freeze dried for three days, ground, and stored at room temperature in a dark place. A modified procedurewas used for sample extraction [31]. The sample (one gram) was extracted separately with (a) 12 mL of 80% methanol (80% MeOH) and (b) 10 mL of chloroform (CHL) plus 1 mL of distilled water for 30 min on an orbital shaker at 210 RPM. The extract was sonicated for 1 min at room temperature (Sonorex Digitec DT 255 H, 160/640 W, Bandelin, Berlin, Germany) and centrifuged at 24,400× g for 10 min at room temperature (Rotanta 460R, Hettich, Germany). The supernatant was transferred into an evaporation flask and the rest matrix was re-extracted using the same procedure. The supernatants were mixed and evaporated at 30 °C on a rotary evaporator (Büchi AG, Flawil, Switzerland). After evaporation, the flask containing the evaporated extracts was weighed and the extract were resuspended with the corresponding extraction solvent: (a) 10 mL of 80% MeOH or (b) 10 mL CHL. One mL of resuspended extract was collected for HPLC−HRMS analysis; the rest of the extract was evaporated, and then the flask was weighed again. These residual extracts were resuspended in dimethyl sulfoxide (DMSO) and collected in order to assay anti-inflammatory and antioxidant activities. For GC−MS analysis, the procedure was the same as the previous CHL procedure but the extraction solvent was hexane:diethyl ether (3:1, v/v) and the final resuspending volume was 2 mL. All extracts were prepared in triplicate and stored at −18 °C. For 1H-NMR spectroscopy, the extraction was performed based on a modified protocol proposed by Kim, Choi, and Verpoorte (2010) [32]. Each 50.0 mg of dried sample was extracted with 600 μL of 80% MeOH for 30 min with shaking. The extracts were sonicated for 5 min at room temperature and centrifuged at 24,400× g for 10 min to separate the extract from the matrix. After collecting the supernatants, the extraction process was repeated with 600 µL of the same solution. Both supernatants were mixed and evaporated using a stream of nitrogen gas. The residue was dissolved in 400 μL of deuterated methanol-D4 and 400 μL of KH2PO4 buffer in deuterated water (pH 6.0) containing 0.1% TSP-D4 (trimethylsilylpropionic acid, sodium salt-D4, wt/wt). The mixture was centrifuged at 24,400× g for 10 min at room temperature. Supernatants (600 μL) were transferred to 5 mm NMR tubes and subjected to 1H-NMR analyses (see Section 2.2.3).

2.2. Chemical Analysis

2.2.1. Liquid Chromatography−Mass Spectrometry (LC−MS) Analysis

A non-targeted screening analysis of the crude extracts (80% MeOH) from the five Pleurotus species was performed using the LC-HRMS system consisting of the Ultimate 3000 UPLC chromatograph Thermo Fisher Scientific (Waltham, MA, USA) with a Q-TOF high-resolution mass spectrometer (Impact II, Bruker Daltonic, Bremen, Germany). An Acclaim RS-LC 120 C18 column (2 µm, 2.1 × 100 mm, Thermo Scientific, Waltham, MA, USA) was used for chromatographic separation. The column temperature was set at 35 °C. Two types of polar phases (A1—5 mM ammonium formate (COONH4) and A2—0.1% formic acid (HCOOH) in water) were chosen as the mobile phase due to the differing ionization properties of the molecules. Methanol (MeOH) was used as the organic phase (B). In order to ensure the widest possible range of polarity of the analytes contained in the extracts, a gradient ranging from 2% to 100% organic phase (MeOH) over 26 min and then isocratic for 10 min with 100% MeOH, was used for analysis. Each sample was analyzed with both mobile phase systems (A1/B, A2/B). The flow rate of the mobile phase was 0.25 mL/min and the injection volume of the sample was 5 μL. The m/z range of the monitored masses was between 60 and 1500. For the non-target analysis, an electrospray ionization (ESI) in both positive and negative mode data was applied. The data were collected in ddMS2 mode in order to contain fragmentation spectra of the most important ions for later identification.
The content of ergosterol was determined using the same LC−MS system with APCI ionization in positive mode. The mobile phase consisted of 0.2% formic acid (polar phase A) and methanol (organic phase B). An elution gradient was used: for the first minute the mobile phase was kept on 60% B, then the percentage of B grew to 100% in 6 min, and remained on this level for the next 10 min. Then, the level of B decreased to the starting conditions (60% B) and was kept at this level for 5 min to achieve system equilibration. The same chromatographic column that was used in the non-target analysis was used. The injection volume of samples was 5 μL. The flow rate of the mobile phase was set to 0.35 mL/min and the column temperature was set to 35 °C. Ergosterol was identified by the commercially available standard (Pharmaceutical Secondary Standard; Certified Reference Material, Sigma-Aldrich, St. Louis, MO, USA). Detailed mass spectrometry measurement parameters for both ion source analyses are shown in Table S1. The identification of ergosterol was based on retention time and the exact mass of the ion [M + H]+ = 397.3470, which was also used as a quantification ion, and [M-H2O]+ = 379.3365, which was used as a confirmation ion. The following values were calculated for ergosterol: LOD = 121.8 ng/mL, LOQ = 406.1 ng/mL, and a precision (RSD) of 2.34%. Ten points of the concentration range 20–2500 ng/mL were used for calibration curve construction and the R2 of the curve was 0.9991. A carryover effect was monitored by measuring solvent blanks between the samples. The quantification of analytes was performed using TASQ 2.2 software (Bruker Daltonik, Bremen, Germany).
In the non-target analysis, the data acquisition and the first step of data processing was performed by Otof Control 5.2, Bruker Compass Hy Star 5.1 and DataAnalysis 5.2 software (all Bruker Daltonik, Bremen, Germany). The results were then processed using XCMS (Scripps Research) and Mzmine software (authors: Matej Orešič, Mikko Katajamaa) and based on these outputs, sets of difference signals (features) were identified for each type of crude extract. The total number of identified features (about 120,000) was subsequently reduced to the resulting several hundred potential metabolites by applying criteria like intensity, peak shape, m/z and retention time, and exclusion of isotopic ions and adducts. The reduced dataset (5000 features) with the highest importance was normalized (Pareto scaling), cleaned using principal component analysis (PCA) in the online free software MetaboAnalyst (v 5.0, Xia Lab, Ste. Anne de Bellevue, QC, Canada) by selection of the most important features responsible for the biggest differences among samples. The final number of features was then reduced to 330 by removing in-source fragment ions and other artifacts.

2.2.2. Gas Chromatography Coupled to Mass Spectrometry (GC−MS) Analysis

For GC−MS, a modified sample preparation protocol by Pedneault et al. (2007) was used [33]. GC Agilent Technologies 7890A, MS 5975C (Palo Alto, CA, USA) was used for the analysis of non-polar compounds extracted with hexane:diethyl ether (3:1, v/v). One µL of extract was injected in split mode (1:12) into a system equipped with an Agilent J&W DB-5MS column (Palo Alto, CA, USA). The separation was performed using a temperature gradient program, starting at a temperature of 60 °C, which then increased to 280 °C in 3 °C increments. Mass spectra were collected in TIC mode.

2.2.3. Proton Nuclear Magnetic Resonance (1H-NMR) Analysis

The 1H-NMR parameter for spectral acquisition was used according to the protocol by Mascellani et al. (2021) [34]. All spectra were recorded at 298 K (25 °C) on a Bruker Avance III HD spectrometer equipped with a broadband fluorine observation (BBFO) SmartProbe™ with z-axis gradients (Bruker BioSpin GmbH, Rheinstetten, Germany), operating at a 1H-NMR frequency of 500.18 MHz. The spectrometer transmitter was locked to deuterated MeOH and all spectra were recorded with the Bruker pulse sequence ‘noesypr1d’ for presaturation of the water signal at 4.704 ppm. Each sample was collected in 64 k data points after 128 scans and 4 dummy scans using a spectral width of 8000 Hz. The receiver gain was set to 18, the relaxation delay was 1 s, the acquisition time was 4 s, and the mixing time was 0.1 s. The free induction decay was multiplied by 0.3 Hz (line broadening) before Fourier transformation. TSP was used to calibrate to 0.0 ppm. The acquired 1H-NMR spectra were phased and corrected for baseline using Chenomx NMR suite 9 software professional edition (Chenomx Inc., Edmonton, AB, Canada). The assignment of signals was performed using spiked samples, in-house, and built-in databases. The spiking for ergothioneine was performed using the commercially available standard (purity ≥ 98.0%, Sigma-Aldrich, St. Louis, MO, USA) to confirm the annotation.

2.3. Antioxidant Activity

2.3.1. Radical Scavenging Assay Using 2,2-Diphenyl-1-picrylhydrazyl (DPPH)

The ability of the tested samples to inhibit DPPH (2,2-diphenyl-1-picrylhydrazyl; Sigma-Aldrich, St. Louis, MO, USA) radicals was determined using the method described by Sharma and Bhat (2009) [35] with modification. Initially, two-fold serial dilutions of each sample were prepared in analytical grade MeOH (VWR, Radnor, PA, USA) in 96-well microtiter plates. Subsequently, 100 μL of freshly prepared 0.25 mM DPPH in MeOH was added to each well and mixed with the samples, creating a concentration range of 512 to 8 μg/mL. Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; Sigma-Aldrich, St. Louis, MO, USA) was used as a positive control at concentrations of 64, 32, 16, 8, 4, 2, and 1 μg/mL, with MeOH used as a blank. The absorbance was measured at 517 nm using a Synergy H1 multi-mode reader (BioTek, Winooski, Winooski, VT, USA). Results were expressed as half-maximal inhibitory concentrations (IC50 in μg/mL) and Trolox equivalents (mg TE/g extract).

2.3.2. Oxygen Radical Absorbance Capacity (ORAC) Assay

The sample’s ability to retard the AAPH-induced oxidant decay of fluorescein (FL) was measured by the method of Ou and Hampsch-Woodill (2001) [36] with modification. All samples and reagents were prepared and diluted in 75 mM phosphate buffer (pH adjusted to 7.0 with HCl). Inorganic acids and salts used for buffer preparation included monopotassium phosphate (KH2PO4, Lach-ner, Neratovice, Czech Republic), dipotassium phosphate (K2HPO4, Sigma-Aldrich, St. Louis, MO, USA), and hydrochloric acid (Penta, Czech Republic). The outer wells of black absorbance 96-well microtiter plates were filled with 200 μL of distilled water in order to provide better thermal mass stability, as suggested by Held (2005) [37]. Afterwards, 25 μL of each sample was transferred to the plates, diluted with 150 μL of fluorescein (54 nmol/L) (Sigma-Aldrich, St. Louis, MO, USA), and incubated at 37 °C for 10 min. To initiate the reaction, 25 μL of 153 mmol/L AAPH (2,2′-azobis(2-amidinopropane) dihydrochloride, Sigma-Aldrich, St. Louis, MO, USA) was added to each well. Fluorescence decay was measured at one-minute intervals for two hours with excitation and emission wavelengths set at 494 and 519 nm. Trolox at 8, 4, 2, 1, and 0.5 μg/mL was used as a positive control with the buffer used as a blank. Samples were tested at a final concentration of 1024 μg/mL. The ORAC values were calculated as the area under the curve (AUC) values and compared with the calibration curve of Trolox, as previously suggested by Ou and Hampsch-Woodill (2001) [36]. Results were expressed as Trolox equivalents (mg TE/g extract).

2.4. COX-2 Anti-Inflammatory Activity Assay

Human recombinant cyclooxygenase-2 (COX-2; Sigma-Aldrich, St. Louis, MO, USA) was used in an in-vitro enzymatic assay. COX-2 (0.5 unit/reaction) was added to 180 µL of 100 mM Tris buffer (pH 8.00) containing 5 μM hematin (porcine), 18 mM (L)-(−)-epinephrine, and 50 μM Na2EDTA. Mushroom extracts in 80% MeOH were evaporated and dissolved in DMSO (VWR, Radnor, PA, USA). The final concentration of the extracts in the reaction was 10 μg/mL. Pure DMSO was used as a blank and (S)-(+)-ibuprofen (Sigma-Aldrich, St. Louis, MO, USA) was used as a reference inhibitor (positive control). Aliquots of 10 μL of extract were incubated with the reaction mixture for 5 min at room temperature. The reaction was then initiated by the addition of 5 µL of 10 μM arachidonic acid and incubated for 20 min at 37 °C. The reaction was stopped by the addition of 20 µL of 10% formic acid (v/v). The inhibitory activity was calculated as the percentage inhibition of prostaglandin E2 (PGE2) production compared to the blank. The concentration of PGE2 was quantified using a prostaglandin E2 ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA). Samples were diluted (1:15) and incubated according to the manufacturer’s instructions. Absorbance was measured at 405 nm using a Tecan Infinite M200 microplate reader (Tecan Group, Männedorf, Switzerland). The results were expressed as the percent inhibition of the sample compared to the blank.

2.5. Cell-Based Assays

The THP-1-XBlue™-MD2-CD14 cell line was purchased from Invivogen (San Diego, CA, USA) and was cultured as reported previously by Hosek et al. (2011) [38]. In more detail, the cells were cultivated at 37 °C in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified atmosphere containing 5% CO2. The WST-1 assay was used to test the effects of extracts on the viability of using the THP-1-XBlue™-MD2-CD14 cells according to the manufacturer’s instructions. The antiproliferative activity of the test extracts from P. flabellatus 5013, P. opuntiae 5012, P. ostreatus 5175 Florida, and P. pulmonarius KZ50 was tested at five concentrations ranging from 0.25 to 20 μg/mL. Based on these results, the non-toxic extract concentration of 10 µg/mL was used for subsequent cell-based assays.

2.5.1. Cellular Antioxidant Activity (CAA) Assay

The antioxidant activity of test extracts was measured using the method of Wolfe and Liu (2007) [39] with some modifications, as reported by Malanik et al. (2020) [40]. THP-1-XBlue™-MD2-CD14 cells were pre-incubated for 1 h in a serum-free RPMI 1640 medium containing 25 μM 2′,7′-dichlorodihydrofluorescein-diacetate (DCFH2-DA; Sigma-Aldrich, St. Louis, MO, USA) dissolved in DMSO [the final concentration of DMSO in the medium was 0.1% (v/v)] at 37 °C. After that, the cells were centrifuged, washed with phosphate-buffered saline, re-suspended in serum-free RPMI 1640 medium, and placed into 96-well plates in triplicates—60,000 cells/well. The cells were then incubated with the extracts for 1 h and after that, 2,2′-azobis(2-methylpropionamidine) dihydrochloride (AAPH; Sigma-Aldrich, St. Louis, MO, USA) was added (at a final concentration of 600 µM) to induce the generation of ROS. The plate was immediately placed into a FLUOstar Omega microplate reader (BMG Labtech) tempered at 37 °C. The level of oxidized fluorescent 2′,7′-dichlorfluorescein (DCF) was measured every 5 min for 1 h (excitation wavelength at 485 nm; emission at 538 nm). Each plate included triplicate control and blank wells: control wells contained cells treated with DCFH-DA and AAPH; blank wells contained cells treated with the dye and serum-free RPMI 1640 medium without AAPH. Quercetin (Koch-Light Laboratories, Haverhill, UK) was used as a positive control at the same concentration as the test compounds at a concentration of 10 μg/mL. The solvent (80% MeOH) was used as the negative control (NC).
After the blank was subtracted from the fluorescence readings, the area under the curve of fluorescence versus time was integrated to calculate the CAA values of the test compounds: CAA unit = 100 − (∫SA/∫CA) × 100, where ∫SA is the integrated area under the sample fluorescence versus time curve and ∫CA is the integrated area obtained from the control curve.

2.5.2. Detection of the Activation of NF-κB/AP-1

The anti-inflammatory activity of the extracts was also investigated in terms of their effect on NF-κB/AP-1 signaling in lipopolysaccharide (LPS)-stimulated THP-1-XBlue™-MD2-CD14 cells (Invivogen, San Diego, CA, USA). The cell line expresses an NF-κB/AP-1-inducible secreted embryonic alkaline phosphatase (SEAP) reporter gene. The cells were incubated for 24 h with test extracts dissolved in 80% MeOH at a concentration of 10 µg/mL. Solvent alone was used as a negative control (NC) and 10 μM prednisone was used as a positive control (PC).

2.6. Determination of the Content of Glucans

The “MUSHROOM and YEAST β-GLUCAN” K-YBGL 07/11 analytical set (Megazyme International, Wicklow, Ireland) was used for the determination of the total α- and β-glucans [41]. The assay determines the difference between the glucose content after total acidic hydrolysis of glucans and specific enzymatic hydrolysis of starch-like α-glucans. Samples were solubilized in concentrated hydrochloric acid (37%; 10 N) and then hydrolyzed with 1.3 mol/L hydrochloric acid at 100 °C for 2 h. Total hydrolysis was completed via incubation with a mixture of exo-(1–3)-β-glucanase and β-glucosidase. Starch-like α-glucans were solubilized in 2 mol/L potassium hydroxide and the mixture was neutralized with an excess of 1.2 mol/L sodium acetate buffer (pH 3.8). The dissolved glucans were then hydrolyzed with amyloglucosidase. The β-glucan, or non-starch glucan, content was calculated as the difference between the glucose content after total acidic hydrolysis of glucans and specific enzymatic hydrolysis of α-glucans. All measurements were made in triplicate.

2.7. Statistical Analysis

Statistical analyses were carried out using Statistica (TIBCO Software, CA, USA) and MetaboAnalyst v. 5.0 (Xia Lab, Ste. Anne de Bellevue, QC, Canada). The data are presented as means ± SD. To determine the significance of sample differences, one-way ANOVA, followed by a post-hoc Tukey test (α = 0.01) was used. For cell-based assays, the statistical analyses were carried out using IBM SPSS for Windows, software version 26.0 (Armonk, NY, USA). The data were graphed as a mean ± SD. Comparisons between groups were made using a Kruskal–Wallis test, followed by pair-wise comparison with Bonferroni correction.

3. Results and Discussion

3.1. Extraction Yield of Mushroom Extracts

Table 1 shows the extraction yields from mushroom samples. There was a significant difference in the extraction yield between the extraction solvents. The yield of 80% MeOH samples ranged between 28.4 and 32.9% and was higher than the yield of CHL extracts, which ranged from 2.5–4.5%.
The difference may have been caused by the low content of lipids and nonpolar compounds in the mushroom samples. Eighty percent MeOH has a high extraction power for a broad spectrum of the polar or slightly nonpolar compounds present in mushrooms. According to Alam et al. [42], dried mushrooms of three Pleurotus species were determined to contain 4.4–4.6% lipids, 38.8–42.8% carbohydrates, 20.6–24.6% proteins, 8.3–9.4% ash, and 22.9–24.3% fiber. According to Chaiharn et al. [43], the extraction yield of two P. ostreatus samples was 16.00% and 22.25% for water and 6% and 10% for MeOH.

3.2. LC−MS Analysis of Mushroom Extracts

Preliminary identification based on the screening data obtained from chloroform extracts indicated the presence of a number of lipids such as phospholipids and acyl-glycerol- and steroid-type compounds. Higher molecular weight compounds, such as oligosaccharides, peptides, and their conjugates with smaller molecules, were found in 80% MeOH extracts, as indicated by the collected MS2 spectra. Untargeted HPLC−HRMS analysis by PCA score plot based on 330 of the most important features (Figure S1) showed specific differences between P. flabellatus and other samples, which was confirmed by hierarchical clustering (Figure S2). Subsequent tentative identification of the most important features using MS2 analysis showed that most of them were related to higher molecular structures, especially oligosaccharides and peptides.
An example of an identified low molecular weight metabolite with possible biological activity in these extracts was ergothioneine, whose identity was also confirmed by the fragment spectrum (Figure S3). Another abundant compound identified in the analysis was ergosterol (Table 2).
The highest ergosterol content was found in P. flabellatus 5013 and the lowest content was in P. ostreatus Sylvan Ivory. The ergosterol level in selected mushroom samples ranged from 214.5–163.7 mg/kg of d.w. powder and 538.5–805.3 µg/g of dry extract.

3.3. GC−MS Analysis of Mushroom Extracts

The predominant compound in all measured extracts was ergosterol, a precursor of vitamin D2. The other most abundant compounds were isomers of 2-butyl-2-octanol, dodecanol, and 2-hexyl-1-octanol derivatives, which are common in mushrooms [44]. The P. ostreatus 5175 Florida showed the greatest difference among the samples because of the presence of octadecadienoic acid derivatives (Figure S4).

3.4. NMR Analysis of Mushroom Extracts

Table 3 shows the results of the 1H-NMR spectroscopy of selected analytes. The most abundant were the saccharides trehalose and mannitol, followed by specific amino acids, organic acids, and amines including choline and ergothioneine. The highest content of ergothioneine was detected in P. flabellatus 5013. In general, the ergothioneine content was higher in lesser-known species compared to P. ostreatus samples. The most abundant substance was trehalose (105.0–347.7 mg/g of dry extract); however, in P. flabellatus 5013, the mannitol content was higher than trehalose. The content of mannitol ranged from 18.14 to 144.3 mg/g of the extract and the lowest mannitol level was found in P. ostreatus 5175 Florida. Since all tested mushrooms were cultivated in similar conditions, this variability may be mainly caused by genetic differences and subsequent changes in metabolic pathways. According to Lin et al.’s [45] phylogenetic analysis of Pleurotus species, P. ostreatus and P. flabellatus are the most distinct among the tested species, which is in agreement with the results of our metabolomic and bioactivity investigations, wherein usually these two species are the most distinct.

3.5. Content of Glucans

The total glucan content (Table 4) ranged from 35.8 ± 0.3% to 49.0 ± 0.3% of d.w. and P. opuntiae 5012 had the highest content of α-glucans (4.5–9.8%). The range of β-glucan content was 31.53 ± 0.6% to 43.3 ± 0.6% w/w and P. ostreatus 5175 Florida had the highest β-glucan content of all the samples (43.3 ± 0.6%, w/w). According to Avni et al. [46], the total glucan content ranged from 20.25 ± 0.52% to 48.27 ± 0.68% in Pleurotus spp. and the α-glucan content was 0.47 ± 0.02% to 4.57 ± 0.06%. Lam and Okello [47] determined that the total glucan content of P. ostreatus PL 132 was 27.1% (w/w) and the β-glucan content was 23.9% (w/w). The differences in glucan levels may have been caused by genetic factors.

3.6. Antioxidant Activity

There was a difference in ORAC and DPPH antioxidant activity between the different solvent extracts (Table 5). The IC50 of CHL extracts was <0.68 mg of TE (Trolox equivalent)/g extract, which is considered very low (data not shown). The activity of 80% MeOH extracts ranged from 4.3 to 24.9 mg of TE/g extract in the DPPH assay and 21.7 to 63.9 mg of TE/g extract in the ORAC assay. P. flabellatus 5013 was the most active species in both assays.
The advantage of CAA assays over ORAC and DPPH assays is the involvement of the cellular environment in the activity [48]; however, our results in the CAA assay did not confirm the promising activity of the P. flabellatus 5013 extract. None of the tested extracts had significantly higher activity than the quercetin control. The observed discrepancy might be explained by the different mechanisms tested in chemical-based antioxidant assays (e.g., ORAC and DPPH) and CAA, a cell-based assay. For an extract to be active in the CAA assay, first, the cellular membrane must be crossed by the active constituents. Secondly, the antioxidants must then scavenge various types of peroxyl radicals and other ROS formed in a cellular environment, which are obviously different from those formed in ORAC or DPPH assays. The tested extracts proved inactive in either one of these two aspects or both [48].
Bakir et al. [49] measured the DPPH antioxidant activity in P. ostreatus stored for 24 h at 20 °C and obtained an IC50 of 321 μg/mL, while a sample stored at −40 °C had significantly decreased antioxidant activity with an IC50 of 3486 μg/mL. The IC50 range in our study was 200.4 to 1134.0 μg/mL. We used three-day lyophilized mushroom samples, stored frozen and our IC50 results are similar to those of Bakir et al. [49]. The antioxidant activity of mushroom extract may be linked to ergothioneine (ERG), a water-soluble thiol derivative of histidine, which was previously shown to be associated with antioxidant activity in vitro and in vivo [50]. Many studies confirmed the presence of ergothioneine in various Pleurotus species [29,51,52,53].
According to Halliwell, Cheah, and Tang (2018), the ERG content in food is quite low, yet the human body can accumulate it efficiently. ERG is transported in the blood via a specific transporter (OTCN1) and ERG levels appear to decline during neurodegenerative and cardiovascular disorders, which are associated with oxidative stress. This suggests that ERG may play an important role as a dietary antioxidant. The ERG content in various foods is variable. P. eryngi, for example, was found to contain 541.7 mg of ERG per kg dry weight and in other mushrooms, it ranged from 5.8 to 1812.4 mg/kg d.w [50]. The ERG content of P. cintronopileatus was 3.94 mg/g d.w. compared to 1.21 mg/g d.w. in P. ostreatus [52], which indicated that some lesser-known species of Pleurotus could contain a higher concentration than P. ostreatus. A few non-mushroom foods such as tempeh have a high ERG content (2011.3 mg/kg), but foods like rice, milk, nuts, beans, spices, and vegetables have significantly lower ERG levels at about 49.2 mg/kg d.w. Only fungi are considered to have the necessary biosynthetic apparatuses for ERG biosynthesis and its presence in tempeh is perhaps the result of culturing with Rhizopus fungi [50]. Dubost et al. [54] determined that P. ostreatus contained 2010 mg of ERG per kg d.w. and P. eryngii had 1720 mg ERG/kg d.w., which is comparable to our results.
Tsiapali et al. [55] showed that polysaccharides, such as glucans, have only weak in vitro free radical scavenging ability and may actually stimulate free radical activity in murine macrophages, increasing the level of reactive oxygen species associated with immunomodulation. Trehalose, a disaccharide found in our samples in large quantities, was also proven to decrease oxidative stress in vivo by enhancing the expression of antioxidant genes [56]. According to Radbakhsh et al. [57], trehalose was effective in increasing the total antioxidant capacity and thiol groups in serum in an experimental type 2 diabetes rat model. J.-H. Liu et al. [58] claimed that mannitol acted like a free-radical scavenging agent in vivo against peroxyl radicals and Pelle et al. [59] showed that mannitol was able to protect DNA against UV damage in vivo but was not effective against oxygen radicals, as determined by increased malondialdehyde as a marker level in vivo. Results published by Meza-Menchaca et al. [60] demonstrated that ergosterol peroxide may also be linked to antioxidant activity. The analysis of antioxidant activity in the presence of 80% MeOH extract constituents showed a high correlation of ERG content with IC50 (R = −0.71%) and nicotinate content (−0.90%) (the lower IC50 means higher antioxidant activity). Nicotinate or niacin (vitamin B3) is part of an important redox agent in the NAD(P)+/H system [61] and, therefore, has the ability to prevent oxidative stress [62,63] and act as an anti-inflammatory agent [63].

3.7. Anti-Inflammatory Activity

In the COX-2 inhibitory assay, the non-polar CHL extracts were more active than the 80% MeOH extracts (Table 6), which were virtually inactive and did not even reach the 50% inhibition level. The CHL extract activity was 43.6% to 85.0% of the control. The most active extract in the COX-2 assay was from P. flabellatus 5013. In the NF-κB/AP-1 inhibition assay, the extract activity ranged from 72.7% to 83.4% of the NC, while the inhibitory effect of prednisone (PC) was 79.2 ± 8.0%. The most active sample was P. pulmonarius KZ50. Each assay involves a different mechanism, so the results are not fully comparable.
As reported in previous studies, ergosterol may also be linked to anti-inflammatory and immunomodulatory effects. Ergosterol decreased p-NF-κB and COX-2 expression in a mouse model of diabetic nephropathy [64]. Ergosterol is one of the most abundant metabolites in many fungal species and it was detected in the mushroom extracts in our study as well as in other studies [65,66,67,68]. Previous studies suggested that ergosterol, a provitamin form of vitamin D2 whose mechanism of effect is unclear, is beneficial to human health by decreasing the risk of inflammatory disease. According to clinical studies, vitamin D deficiency is associated with inflammatory health risks [69].
The work of Du et al. [70] dealt with different types of glucans, including those that possess immunomodulatory and anti-inflammatory effects, mediated through cytokines such as TNF-α. The extract from P. ostreatus 5175 Florida was determined to contain the highest amount of total glucans and β-glucans and this may explain why it was the most active in inhibiting NF-κB/AP-1 activity. According to Deo et al. [71], an anti-inflammatory assay of P. ostreatus extract showed over 90% inhibition of TNF-α in the LPS-stimulated mouse macrophage cell 264.7.
Trehalose, which was also assayed in our study, was found to suppress NF-κB pathway activation in cultured cells [72]. The extract of P. ostreatus 5175 Florida was most effective at inhibiting NF-κB (72.2 ± 7.7% of NC), while the lowest activity was recorded for P. flabellatus 5013 extract, which correlated with the lowest measured trehalose level. However, it was reported that increasing the dietary level of trehalose by adding it to food may increase the risk of severe Clostridium infection in the gut [73].
Jedinak et al. [11] presented evidence that the P. ostreatus Florida extract had anti-inflammatory activity as determined by an NF-κB/AP-1 assay in murine splenocytes and it may be effective as a dietary supplement for the reduction of inflammation. In the study, mushroom extracts were added to LPS-activated RAW264.7 mouse macrophages and an extract concentration of 100 µg/mL decreased TNF-α levels from 15.4 to 5.87 ng/mL, IL-6 from 16.1 to 1.16 ng/mL, and IL-12 from 108.8 to 39.2 ng/mL compared controls without extract.
An in vivo study of Wistar rats using the carrageenan-induced paw edema model of inflammation compared the anti-inflammatory activity of dried powdered P. ostreatus with an acetone extract of the same mushroom. The powdered sample at doses of 250–1000 mg/kg exerted a significant inhibition of rat paw edema, but the effect was not dose-dependent. The acetone extract of P. ostreatus (500 mg/kg) showed a maximum 87% inhibition of late phase inflammation, and this was also not dose-dependent [74].

4. Conclusions

In our study, we examined the biological activities of several species of mushrooms of the Pleurotus genus, including lesser-known varieties, and attempted to identify the compounds that were responsible for the observed effects. There is evidence that the less common varieties and species may have greater potential for antioxidant and anti-inflammatory properties than the conventional varieties. In the measurement of the total and β-glucans, the highest content was found in P. ostreatus, but there was relatively little difference in the content among the other species. P. flabellatus 5013 contained the highest level of ergosterol and mannitol was the most abundant compound determined. The results of the in vitro assays were confirmed by in vivo assays. Pleurotus flabellatus 5013 extract was the most effective in the antioxidant assay, which may be linked to the higher measured level of ergothioneine. In other samples, the most abundant compound was trehalose. In antioxidant assays, the 80% MeOH extracts displayed activity, while the CHL extracts did not. These results may also be linked to the ergothioneine content, as confirmed by 1H-NMR and LC−MS analysis of the extracts. The COX-2 anti-inflammatory assay showed that CHL extracts were more active than 80% MeOH extracts. The ergosterol content determined in our study may be associated with this activity. The P. ostreatus 5175 Florida extract was the most active in the NF-κB inhibition assay, and this may be linked to the fact that it contained the highest total glucan content. On the other hand, P. flabellatus 5013, which had the highest antioxidant activity, was found to contain the lowest amount of total and β-glucans. A clinical trial to test the potential therapeutic effects of Pleurotus extracts ought to be conducted to confirm the results of this study.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antiox11081569/s1, Figure S1: PCA of analyzed Pleurotus genus samples (5012—P. opuntiae 5012; 5175—P. ostreatus 5175 Florida; FLAB—P. flabellatus 5013; IVORY—P. ostreatus Sylvan Ivory; PUL—P. pulmonarius KZ50); Figure S2: Cluster analysis of analyzed Pleurotus genus samples (5012—P. opuntiae 5012; 5175—P. ostreatus 5175 Florida; FLAB—P. flabellatus 5013; IVORY—P. ostreatus Sylvan Ivory; PUL—P. pulmonarius KZ50), Figure S3: Annotated HPLC−HRMS fragment spectrum of ergothioneine; Figure S4: Tentatively annotated GC chromatogram (a) isomers of 2-butyl-2-octanol (b) dodecanol derivatives (c) 2-hexyl-1-octanol derivatives (d) octadecadienic acid derivatives (e) ergosterol, Table S1: Mass spectrometer parameter settings.

Author Contributions

Conceptualization: P.K., J.H., and I.J.; methodology: P.K., P.M., J.T. (Jan Tauchen), and J.S.; writing—original draft preparation: J.S.; writing—review and editing: P.K., P.M., and J.T. (Jan Tauchen); supervision: P.K., P.M., J.H., and P.L.; investigation: J.S., P.H., P.L., J.T. (Jan Tauchen), J.T. (Jakub Treml, M.B., R.B., P.M., A.S. and A.M.; project administration: P.K.; funding acquisition: P.K. and J.T. (Jakub Treml). All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the European Regional Development Fund—Project “Centre for the investigation of synthesis and transformation of nutritional substances in the food chain in interaction with potentially harmful substances of anthropogenic origin: comprehensive assessment of soil contamination risks for the quality of agricultural products” (number CZ.02.1.01/0.0/0.0/16_019/0000845); by the National Agency for Agricultural Research of the Ministry of Agriculture of the Czech Republic under project number QK1910209; by the Research Infrastructure METROFOOD-CZ supported by the Ministry of Education, Youth, and Sports of the Czech Republic under project number LM2018100; and by Masaryk University, Specific research—support for student projects MUNI/A/1654/2020—Testing of biological activity of selected natural substances in vitro.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in Table 1, Table 2, Table 3, Table 4, Table 5 and Table 6 and Table S1 and Figures S1–S4.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Roncero-Ramos, I.; Delgado-Andrade, C. The Beneficial Role of Edible Mushrooms in Human Health. Curr. Opin. Food Sci. 2017, 14, 122–128. [Google Scholar] [CrossRef]
  2. Guillamón, E.; García-Lafuente, A.; Lozano, M.; D’Arrigo, M.; Rostagno, M.A.; Villares, A.; Martínez, J.A. Edible Mushrooms: Role in the Prevention of Cardiovascular Diseases. Fitoterapia 2010, 81, 715–723. [Google Scholar] [CrossRef]
  3. Jo, W.-S.; Hossain, M.A.; Park, S.-C. Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms. Mycobiology 2014, 42, 215–220. [Google Scholar] [CrossRef]
  4. Wasser, S.P. Current Findings, Future Trends, and Unsolved Problems in Studies of Medicinal Mushrooms. Appl. Microbiol. Biotechnol. 2011, 89, 1323–1332. [Google Scholar] [CrossRef]
  5. Patel, Y.; Narian, R.; Singh, V.K. Medicinal Properties of Pleurotus Species (Oyster Mushroom): A Review. World J. Fungal Plant Biol. 2012, 3, 1–12. [Google Scholar] [CrossRef]
  6. Hobbs, C. Medicinal Mushrooms: An Exploration of Tradition, Healing, and Culture; Herbs and Health Series; Botanica Press: Williams, OR, USA, 2003; ISBN 9781570671432. [Google Scholar]
  7. Rama Shankar, G.S.; Lavekar, S.D.; Sharma, B.K. Traditional healing practice and folk medicines used by Mishing community of North East India. J. Ayurveda Integr. Med. 2012, 3, 124–129. [Google Scholar] [CrossRef]
  8. Catalogue of Life. Available online: https://www.catalogueoflife.org/col/browse/tree/id/857ebe7fdb1404352630eb1d4da99cf1 (accessed on 29 August 2021).
  9. Deepalakshmi, K.; Mirunalini, S. Pleurotus Ostreatus: An Oyster Mushroom with Nutritional and Medicinal Properties. J. Biochem. Technol. 2014, 5, 718–726. [Google Scholar]
  10. Enshasy, H.; Maftoun, P.; Johari, H.J.; Soltani, M.; Malik, R.; Othman, N. The Edible Mushroom Pleurotus Spp.: I. Biodiversity and Nutritional Values. Int. J. Biotechnol. Wellness Ind. 2015, 4, 67–83. [Google Scholar] [CrossRef]
  11. Jedinak, A.; Dudhgaonkar, S.; Wu, Q.; Simon, J.; Sliva, D. Anti-Inflammatory Activity of Edible Oyster Mushroom Is Mediated through the Inhibition of NF-ΚB and AP-1 Signaling. Nutr. J. 2011, 10, 52. [Google Scholar] [CrossRef]
  12. Golak-Siwulska, I.; Kałużewicz, A.; Spiżewski, T.; Siwulski, M.; Sobieralski, K. Bioactive Compounds and Medicinal Properties of Oyster Mushrooms ( Pleurotus sp.). Folia Hortic. 2018, 30, 191–201. [Google Scholar] [CrossRef]
  13. Klaus, A.; Wan-Mohtar, W.A.A.Q.I.; Nikolić, B.; Cvetković, S.; Vunduk, J. Pink Oyster Mushroom Pleurotus Flabellatus Mycelium Produced by an Airlift Bioreactor—the Evidence of Potent in Vitro Biological Activities. World J. Microbiol. Biotechnol. 2021, 37, 17. [Google Scholar] [CrossRef] [PubMed]
  14. Murugesan, A.K.; Gunasagaran, K.S. Purification and Characterization of a Synergistic Bioactive Lectin from Pleurotus Flabellatus (PFL-L) with Potent Antibacterial and in-Vitro Radical Scavenging Activity. Anal. Biochem. 2021, 635, 114450. [Google Scholar] [CrossRef] [PubMed]
  15. Radzi, M.P.M.F.; Azizah, M.; Maininah, T.; Sumaiyah, A. Growth, Yield And Antioxidant Activity of Grey Oyster Mushroom (Pleurotus Pulmonarius) Grown in Sawdust Substrate With The Supplementation Of Alkaline Materials. JAPS J. Anim. Plant Sci. 2021, 31, 1699–1711. [Google Scholar]
  16. Oyetayo, V.O.; Ogidi, C.O.; Bayode, S.O.; Enikanselu, F.F. Evaluation of Biological Efficiency, Nutrient Contents and Antioxidant Activity of Pleurotus Pulmonarius Enriched with Zinc and Iron. Indian Phytopathol. 2021, 74, 901–910. [Google Scholar] [CrossRef]
  17. Nguyen, T.K.; Im, K.H.; Choi, J.; Shin, P.G.; Lee, T.S. Evaluation of Antioxidant, Anti-Cholinesterase, and Anti-Inflammatory Effects of Culinary Mushroom Pleurotus Pulmonarius. Mycobiology 2016, 44, 291–301. [Google Scholar] [CrossRef] [PubMed]
  18. Xu, W.W.; Li, B.; Lai, E.T.C.; Chen, L.; Huang, J.J.H.; Cheung, A.L.M.; Cheung, P.C.K. Water Extract from Pleurotus Pulmonarius with Antioxidant Activity Exerts In Vivo Chemoprophylaxis and Chemosensitization for Liver Cancer. Nutr. Cancer 2014, 66, 989–998. [Google Scholar] [CrossRef] [PubMed]
  19. Pumtes, P.; Rojsuntornkitti, K.; Kongbangkerd, T.; Jittrepotch, N. Effects of Different Extracting Conditions on Antioxidant Activities of Pleurotus flabellatus. Int. Food Res. J. 2016, 23, 173–179. [Google Scholar]
  20. Smiderle, F.R.; Olsen, L.M.; Carbonero, E.R.; Baggio, C.H.; Freitas, C.S.; Marcon, R.; Santos, A.R.S.; Gorin, P.A.J.; Iacomini, M. Anti-Inflammatory and Analgesic Properties in a Rodent Model of a (1→3),(1→6)-Linked β-Glucan Isolated from Pleurotus Pulmonarius. Eur. J. Pharmacol. 2008, 597, 86–91. [Google Scholar] [CrossRef]
  21. Adebayo, E.; Oloke, J.; Olusola, M.; Ajani, R.; Bora, T. Antimicrobial and Anti-Inflammatory Potential of Polysaccharide from Pleurotus Pulmonarius LAU 09. Afr. J. Microbiol. Res. 2012, 6, 3315–3323. [Google Scholar] [CrossRef]
  22. Pandey, A.T.; Pandey, I.; Kerkar, P.; Singh, M.P. Antimicrobial Activity and Mycochemical Profile of Methanol Extract from Pleurotus Flabellatus. Vegetos 2021, 34, 619–629. [Google Scholar] [CrossRef]
  23. Damaris Chinwendu, O. Antioxidant and Antimicrobial Activities of Oyster Mushroom. Am. J. Food Sci. Ant Technol. 2017, 5, 64–69. [Google Scholar] [CrossRef]
  24. Díaz-Godínez, G.; Téllez-Téllez, M.; Rodríguez, A.; Obregón-Barbosa, V.; Acosta-Urdapilleta, M.D.L.; Villegas, E. Enzymatic, Antioxidant, Antimicrobial, and Insecticidal Activities of Pleurotus Pulmonarius and Pycnoporus Cinnabarinus Grown Separately in an Airlift Reactor. BioResources 2016, 11, 4186–4200. [Google Scholar] [CrossRef]
  25. Kumar, K. Role of Edible Mushrooms as Functional Foods—A Review. South Asian J. Food Technol. Environ. 2015, 1, 5454–6445. [Google Scholar] [CrossRef]
  26. Sarangi, I.; Ghosh, D.; Bhutia, S.K.; Mallick, S.K.; Maiti, T.K. Anti-Tumor and Immunomodulating Effects of Pleurotus Ostreatus Mycelia-Derived Proteoglycans. Int. Immunopharmacol. 2006, 6, 1287–1297. [Google Scholar] [CrossRef]
  27. Xia, F.; Fan, J.; Zhu, M.; Tong, H. Antioxidant Effects of a Water-Soluble Proteoglycan Isolated from the Fruiting Bodies of Pleurotus Ostreatus. J. Taiwan Inst. Chem. Eng. 2011, 42, 402–407. [Google Scholar] [CrossRef]
  28. Reis, F.S.; Martins, A.; Barros, L.; Ferreira, I.C.F.R. Antioxidant Properties and Phenolic Profile of the Most Widely Appreciated Cultivated Mushrooms: A Comparative Study between in Vivo and in Vitro Samples. Food Chem. Toxicol. 2012, 50, 1201–1207. [Google Scholar] [CrossRef]
  29. Chen, S.-Y.; Ho, K.-J.; Hsieh, Y.-J.; Wang, L.-T.; Mau, J.-L. Contents of Lovastatin, γ-Aminobutyric Acid and Ergothioneine in Mushroom Fruiting Bodies and Mycelia. LWT 2012, 47, 274–278. [Google Scholar] [CrossRef]
  30. Calabretti, A.; Mang, S.M.; Becce, A.; Castronuovo, D.; Cardone, L.; Candido, V.; Camele, I. Comparison of Bioactive Substances Content between Commercial and Wild-Type Isolates of Pleurotus Eryngii. Sustainability 2021, 13, 3777. [Google Scholar] [CrossRef]
  31. Baek, J.; Roh, H.-S.; Baek, K.-H.; Lee, S.; Lee, S.; Song, S.-S.; Kim, K.H. Bioactivity-Based Analysis and Chemical Characterization of Cytotoxic Constituents from Chaga Mushroom (Inonotus Obliquus) That Induce Apoptosis in Human Lung Adenocarcinoma Cells. J. Ethnopharmacol. 2018, 224, 63–75. [Google Scholar] [CrossRef]
  32. Kim, H.K.; Choi, Y.H.; Verpoorte, R. NMR-Based Metabolomic Analysis of Plants. Nat. Protoc. 2010, 5, 536–549. [Google Scholar] [CrossRef]
  33. Pedneault, K.; Angers, P.; Avis, T.J.; Gosselin, A.; Tweddell, R.J. Fatty Acid Profiles of Polar and Non-Polar Lipids of Pleurotus Ostreatus and P. Cornucopiae Var. ‘Citrino-Pileatus’ Grown at Different Temperatures. Mycol. Res. 2007, 111, 1228–1234. [Google Scholar] [CrossRef] [PubMed]
  34. Mascellani, A.; Natali, L.; Cavallini, A.; Mascagni, F.; Caruso, G.; Gucci, R.; Havlik, J.; Bernardi, R. Moderate Salinity Stress Affects Expression of Main Sugar Metabolism and Transport Genes and Soluble Carbohydrate Content in Ripe Fig Fruits (Ficus Carica L. Cv. Dottato). Plants 2021, 10, 1861. [Google Scholar] [CrossRef] [PubMed]
  35. Sharma, O.P.; Bhat, T.K. DPPH Antioxidant Assay Revisited. Food Chem. 2009, 113, 1202–1205. [Google Scholar] [CrossRef]
  36. Ou, B.; Hampsch-Woodill, M.; Prior, R.L. Development and Validation of an Improved Oxygen Radical Absorbance Capacity Assay Using Fluorescein as the Fluorescent Probe. J. Agric. Food Chem. 2001, 49, 4619–4626. [Google Scholar] [CrossRef] [PubMed]
  37. Held, P. Performing Oxygen Radical Absorbance Capacity Assays with Synergy HT: ORAC Antioxidant Tests. Appl. Note. Available online: https://www.biotek.com/resources/docs/ORAC_Assay_Application_Note.pdf (accessed on 12 August 2022).
  38. Hošek, J.; Bartos, M.; Chudík, S.; Dall’Acqua, S.; Innocenti, G.; Kartal, M.; Kokoška, L.; Kollár, P.; Kutil, Z.; Landa, P.; et al. Natural Compound Cudraflavone B Shows Promising Anti-Inflammatory Properties in Vitro. J. Nat. Prod. 2011, 74, 614–619. [Google Scholar] [CrossRef] [PubMed]
  39. Wolfe, K.L.; Liu, R.H. Cellular Antioxidant Activity (CAA) Assay for Assessing Antioxidants, Foods, and Dietary Supplements. J. Agric. Food Chem. 2007, 55, 8896–8907. [Google Scholar] [CrossRef] [PubMed]
  40. Malanik, M.; Treml, J.; Lelaková, V.; Nykodymová, D.; Oravec, M.; Marek, J.; Šmejkal, K. Anti-Inflammatory and Antioxidant Properties of Chemical Constituents of Broussonetia Papyrifera. Bioorganic Chem. 2020, 104, 104298. [Google Scholar] [CrossRef]
  41. McCleary, B.V.; Draga, A. Measurement of β-Glucan in Mushrooms and Mycelial Products. J. Aoac Int. 2016, 99, 364–373. [Google Scholar] [CrossRef]
  42. Alam, N.; Amin, R.; Khan, A.; Ara, I.; Shim, M.J.; Lee, M.W.; Lee, T.S. Nutritional Analysis of Cultivated Mushrooms in Bangladesh—Pleurotus Ostreatus, Pleurotus Sajor-Caju, Pleurotus Florida and Calocybe Indica. Mycobiology 2008, 36, 228. [Google Scholar] [CrossRef]
  43. Chaiharn, M.; Phutdhawong, W.S.; Amornlerdpison, D.; Phutdhawong, W. Antibacterial, Antioxidant Properties and Bioactive Compounds of Thai Cultivated Mushroom Extracts against Food-Borne Bacterial Strains. Chiang Mai J. Sci. 2018, 45, 1713–1727. [Google Scholar]
  44. Muan, C.; Chonju, H. Volatile components of oyster mushrooms (Pleurotus sp.) cultivated in Korea. Korean J. Mycol. (Korea Repub.) 1992, 19, 299–305. [Google Scholar]
  45. Lin, P.; Yan, Z.-F.; Kook, M.; Li, C.-T.; Yi, T.-H. Genetic and Chemical Diversity of Edible Mushroom Pleurotus Species. BioMed Res. Int. 2022, 2022, 6068185. [Google Scholar] [CrossRef]
  46. Avni, S.; Ezove, N.; Hanani, H.; Yadid, I.; Karpovsky, M.; Hayby, H.; Gover, O.; Hadar, Y.; Schwartz, B.; Danay, O. Olive Mill Waste Enhances α-Glucan Content in the Edible Mushroom Pleurotus Eryngii. Int. J. Mol. Sci. 2017, 18, 1564. [Google Scholar] [CrossRef]
  47. Lam, Y.S.; Okello, E.J. Determination of Lovastatin, β-Glucan, Total Polyphenols, and Antioxidant Activity in Raw and Processed Oyster Culinary-Medicinal Mushroom, Pleurotus Ostreatus (Higher Basidiomycetes). Int. J. Med. Mushrooms 2015, 17, 117–128. [Google Scholar] [CrossRef] [PubMed]
  48. Treml, J.; Večeřová, P.; Herczogová, P.; Šmejkal, K. Direct and Indirect Antioxidant Effects of Selected Plant Phenolics in Cell-Based Assays. Molecules 2021, 26, 2534. [Google Scholar] [CrossRef]
  49. Bakir, T.; Karadeniz, M.; Unal, S. Investigation of Antioxidant Activities of Pleurotus Ostreatus Stored at Different Temperatures. Food Sci. Nutr. 2018, 6, 1040–1044. [Google Scholar] [CrossRef] [PubMed]
  50. Halliwell, B.; Cheah, I.K.; Tang, R.M.Y. Ergothioneine—A Diet-derived Antioxidant with Therapeutic Potential. FEBS Lett. 2018, 592, 3357–3366. [Google Scholar] [CrossRef] [PubMed]
  51. Liang, C.-H.; Ho, K.-J.; Huang, L.-Y.; Tsai, C.-H.; Lin, S.-Y.; Mau, J.-L. Antioxidant Properties of Fruiting Bodies, Mycelia, and Fermented Products of the Culinary-Medicinal King Oyster Mushroom, Pleurotus Eryngii (Higher Basidiomycetes), with High Ergothioneine Content. Int. J. Med. Mushrooms 2013, 15, 267–275. [Google Scholar] [CrossRef]
  52. Kalaras, M.D.; Richie, J.P.; Calcagnotto, A.; Beelman, R.B. Mushrooms: A Rich Source of the Antioxidants Ergothioneine and Glutathione. Food Chem. 2017, 233, 429–433. [Google Scholar] [CrossRef] [PubMed]
  53. Permatasari, W.; Dayanti, D.; Khaerunnisa, I.; Winarni, S. Literatur Review The New Super Antioxidant, Ergothioneine In Pleurotus Ostreatus. Int. J. Health Educ. &Amp; Soc. (IJHES) 2020, 3, 23–33. [Google Scholar] [CrossRef]
  54. Dubost, N.J.; Beelman, R.B.; Peterson, D.; Royse, D.J. Identification and Quantification of Ergothioneine in Cultivated Mushrooms by Liquid Chromatography-Mass Spectroscopy. Int. J. Med. Mushrooms 2006, 8, 215–222. [Google Scholar] [CrossRef]
  55. Tsiapali, E.; Whaley, S.; Kalbfleisch, J.; Ensley, H.E.; Browder, I.W.; Williams, D.L. Glucans Exhibit Weak Antioxidant Activity, but Stimulate Macrophage Free Radical Activity. Free. Radic. Biol. Med. 2001, 30, 393–402. [Google Scholar] [CrossRef]
  56. Mizunoe, Y.; Kobayashi, M.; Sudo, Y.; Watanabe, S.; Yasukawa, H.; Natori, D.; Hoshino, A.; Negishi, A.; Okita, N.; Komatsu, M.; et al. Trehalose Protects against Oxidative Stress by Regulating the Keap1–Nrf2 and Autophagy Pathways. Redox Biol. 2018, 15, 115–124. [Google Scholar] [CrossRef]
  57. Radbakhsh, S.; Ganjali, S.; Moallem, S.A.; Guest, P.C.; Sahebkar, A. Antioxidant Effects of Trehalose in an Experimental Model of Type 2 Diabetes. In Natural Products and Human Diseases; Springer: Berlin, Germany, 2021; pp. 473–480. [Google Scholar]
  58. Liu, J.-H.; Chen, M.-M.; Huang, J.-W.; Wann, H.; Ho, L.-K.; Pan, W.H.T.; Chen, Y.-C.; Liu, C.-M.; Yeh, M.-Y.; Tsai, S.-K.; et al. Therapeutic Effects and Mechanisms of Action of Mannitol During H2O2-Induced Oxidative Stress in Human Retinal Pigment Epithelium Cells. J. Ocul. Pharmacol. Ther. 2010, 26, 249–257. [Google Scholar] [CrossRef] [PubMed]
  59. Pelle, E.; Mammone, T.; Marenus, K.; Maes, D.; Huang, X.; Frenkel, K. Ultraviolet-B-Induced Oxidative DNA Base Damage in Primary Normal Human Epidermal Keratinocytes and Inhibition by a Hydroxyl Radical Scavenger. J. Investig. Dermatol. 2003, 121, 177–183. [Google Scholar] [CrossRef] [PubMed]
  60. Meza-Menchaca, T.; Poblete-Naredo, I.; Albores-Medina, A.; Pedraza-Chaverri, J.; Quiroz-Figueroa, F.R.; Cruz-Gregorio, A.; Zepeda, R.C.; Melgar-Lalanne, G.; Lagunes, I.; Trigos, Á. Ergosterol Peroxide Isolated from Oyster Medicinal Mushroom, Pleurotus Ostreatus (Agaricomycetes), Potentially Induces Radiosensitivity in Cervical Cancer. Int. J. Med. Mushrooms 2020, 22, 1109–1119. [Google Scholar] [CrossRef] [PubMed]
  61. Sinthupoom, N.; Prachayasittikul, V.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Nicotinic Acid and Derivatives as Multifunctional Pharmacophores for Medical Applications. Eur. Food Res. Technol. 2015, 240, 1–17. [Google Scholar] [CrossRef]
  62. Tupe, R.S.; Tupe, S.G.; Agte, V.V. Dietary Nicotinic Acid Supplementation Improves Hepatic Zinc Uptake and Offers Hepatoprotection against Oxidative Damage. Br. J. Nutr. 2011, 105, 1741–1749. [Google Scholar] [CrossRef] [PubMed]
  63. Arauz, J.; Rivera-Espinoza, Y.; Shibayama, M.; Favari, L.; Flores-Beltrán, R.E.; Muriel, P. Nicotinic Acid Prevents Experimental Liver Fibrosis by Attenuating the Prooxidant Process. Int. Immunopharmacol. 2015, 28, 244–251. [Google Scholar] [CrossRef] [PubMed]
  64. Liu, C.; Zhao, S.; Zhu, C.; Gao, Q.; Bai, J.; Si, J.; Chen, Y. Ergosterol Ameliorates Renal Inflammatory Responses in Mice Model of Diabetic Nephropathy. Biomed. Pharmacother. 2020, 128, 110252. [Google Scholar] [CrossRef]
  65. Xiong, M.; Huang, Y.; Liu, Y.; Huang, M.; Song, G.; Ming, Q.; Ma, X.; Yang, J.; Deng, S.; Wen, Y.; et al. Antidiabetic Activity of Ergosterol from Pleurotus Ostreatus in KK-Ay Mice with Spontaneous Type 2 Diabetes Mellitus. Mol. Nutr. Food Res. 2018, 62, 1700444. [Google Scholar] [CrossRef] [PubMed]
  66. Taofiq, O.; Silva, A.R.; Costa, C.; Ferreira, I.; Nunes, J.; Prieto, M.A.; Simal-Gandara, J.; Barros, L.; Ferreira, I.C.F.R. Optimization of Ergosterol Extraction from Pleurotus Mushrooms Using Response Surface Methodology. Food Funct. 2020, 11, 5887–5897. [Google Scholar] [CrossRef] [PubMed]
  67. Bekiaris, G.; Tagkouli, D.; Koutrotsios, G.; Kalogeropoulos, N.; Zervakis, G.I. Pleurotus Mushrooms Content in Glucans and Ergosterol Assessed by ATR-FTIR Spectroscopy and Multivariate Analysis. Foods 2020, 9, 535. [Google Scholar] [CrossRef]
  68. Alexandre, T.R.; Lima, M.L.; Galuppo, M.K.; Mesquita, J.T.; do Nascimento, M.A.; dos Santos, A.L.; Sartorelli, P.; Pimenta, D.C.; Tempone, A.G. Ergosterol Isolated from the Basidiomycete Pleurotus Salmoneostramineus Affects Trypanosoma Cruzi Plasma Membrane and Mitochondria. J. Venom. Anim. Toxins Incl. Trop. Dis. 2017, 23, 30. [Google Scholar] [CrossRef]
  69. Agrawal, D.; Yin, K. Vitamin D and Inflammatory Diseases. J. Inflamm. Res. 2014, 69–87. [Google Scholar] [CrossRef]
  70. Du, B.; Lin, C.; Bian, Z.; Xu, B. An Insight into Anti-Inflammatory Effects of Fungal Beta-Glucans. Trends Food Sci. Technol. 2015, 41, 49–59. [Google Scholar] [CrossRef]
  71. Deo, G.S.; Khatra, J.; Buttar, S.; Li, W.M.; Tackaberry, L.E.; Massicotte, H.B.; Egger, K.N.; Reimer, K.; Lee, C.H. Antiproliferative, Immunostimulatory, and Anti-Inflammatory Activities of Extracts Derived from Mushrooms Collected in Haida Gwaii, British Columbia (Canada). Int. J. Med. Mushrooms 2019, 21, 629–643. [Google Scholar] [CrossRef]
  72. Echigo, R.; Shimohata, N.; Karatsu, K.; Yano, F.; Kayasuga-Kariya, Y.; Fujisawa, A.; Ohto, T.; Kita, Y.; Nakamura, M.; Suzuki, S.; et al. Trehalose Treatment Suppresses Inflammation, Oxidative Stress, and Vasospasm Induced by Experimental Subarachnoid Hemorrhage. J. Transl. Med. 2012, 10, 80. [Google Scholar] [CrossRef]
  73. Collins, J.; Robinson, C.; Danhof, H.; Knetsch, C.W.; van Leeuwen, H.C.; Lawley, T.D.; Auchtung, J.M.; Britton, R.A. Dietary Trehalose Enhances Virulence of Epidemic Clostridium Difficile. Nature 2018, 553, 291–294. [Google Scholar] [CrossRef] [PubMed]
  74. Jayasuriya, W.J.A.B.N.; Handunnetti, S.M.; Wanigatunge, C.A.; Fernando, G.H.; Abeytunga, D.T.U.; Suresh, T.S. Anti-Inflammatory Activity of Pleurotus Ostreatus, a Culinary Medicinal Mushroom, in Wistar Rats. Evid.-Based Complement. Altern. Med. 2020, 2020, 6845383. [Google Scholar] [CrossRef]
Table
Table 1. Yield of Pleurotus mushroom extract with different extraction solvents.
Table 1. Yield of Pleurotus mushroom extract with different extraction solvents.
Sample NameExtraction Yield by Solvent (% w/w d.w.)
80% MeOHCHL
P. flabellatus 501330.8 ± 2.4 a2.7 ± 0.2 b
P. pulmonarius KZ5030.4 ± 0.9 a2.5 ± 0.2 b
P. opuntiae 501228.4 ± 0.6 a3.5 ± 0.3 c
P. ostreatus Sylvan Ivory30.2 ± 2.7 a4.5 ± 0.2 a
P. ostreatus 5175 Florida32.9 ± 2.5 a4.0 ± 0.4 a,c
The a–c within a column means that significance was determined by one-way ANOVA followed by post-hoc Tukey test (p < 0.01).
Table
Table 2. Ergosterol content of 80% MeOH extracts of Pleurotus species.
Table 2. Ergosterol content of 80% MeOH extracts of Pleurotus species.
SampleErgosterol Content
mg/kg of d.w. Powderµg/g of Dry Extract
P. flabellatus 5013214.5 ± 8.1 b805.3 ± 30.2 b
P. pulmonarius KZ50166.3 ± 2.2 a629.7 ± 8.2 a
P. opuntiae 5012163.4 ± 13.1 a604.3 ± 48.3 a
P. ostreatus Sylvan Ivory163.7 ± 8.2 a538.5 ± 27.0 a
P. ostreatus 5175 Florida178.7 ± 3.1 a547.7 ± 9.3 a
The a,b within a column means that significance was determined by one-way ANOVA followed by post-hoc Tukey test (p < 0.01).
Table
Table 3. 1H-NMR spectroscopy of genus Pleurotus mushroom sample 80% MeOH extracts.
Table 3. 1H-NMR spectroscopy of genus Pleurotus mushroom sample 80% MeOH extracts.
CompoundSample
P. flabellatus 5013P. pulmonarius KZ50P. opuntiae 5012P. ostreatus Sylvan IvoryP. ostreatus 5175 Florida
Content (µg/g of Dry Extract)
2-Aminobutyrate398.8 ± 12.7 a512.3 ± 53.9 c257.6 ± 7.2 b323.4 ± 13.5 a214.5 ± 14.9 b
Acetate439.6 ± 14.5 a956.3 ± 125.8 b452.4 ± 21.1 a612.1 ± 30.7 a,b661.1 ± 29.2 b
Nicotinate900.7 ± 72.3 b580 ± 70.1 a,c757.8 ± 53 a,b672.4 ± 53.1 a,b377.5 ± 29.5 c
Tryptophan1080.6 ± 111.1 b569.3 ± 70.4 c275.5 ± 31.4 a397.7 ± 29.9 a,c354.9 ± 19.1 a,c
Valine879.8 ± 10.3 a1264.4 ± 108.8 b761.4 ± 38.1 a785.9 ± 17.6 a584.6 ± 21.8 a
Content (mg/g of dry extract)
Alanine8.35 ± 0.89 a8.43 ± 0.45 a8.15 ± 0.30 a6.76 ± 0.12 a6.14 ± 0.25 a
Aspartate3.714 ± 0.055 a,b6.02 ± 0.44 b10.76 ± 0.35 c4.20 ± 0.13 a8.45 ± 0.33 c
Choline4.40 ± 0.17 b5.39 ± 0.23 a3.915 ± 0.089 b4.58 ± 0.17 a4.25 ± 0.12 a
Ergothioneine6.22 ± 0.47 b3.13 ± 0.21 a4.16 ± 0.13 c2.65 ± 0.14 a2.72 ± 0.15 a
Fumarate1.70 ± 0.27 b3.40 ± 0.24 d4.30 ± 0.12 c4.99 ± 0.22 a3.14 ± 0.12 c,d
Glutamate14.8 ± 1.3 a,b8.87 ± 0.81 c13.40 ± 1.3 a,b,c15.5 ± 1.9 a8.82 ± 0.44 b,c
Glutamine25.92 ± 0.95 b9.75 ± 0.16 c8.26 ± 0.38 c11.358 ± 0.085 a8.72 ± 0.36 a,c
Mannitol144.3 ± 4.6 b31.5 ± 3.1 a24.09 ± 0.88 a18.14 ± 0.53 a13.81 ± 0.61 a
Phenylalanine2.38 ± 0.26 b2.36 ± 0.17 b1.587 ± 0.054 a1.33 ± 0.11 a1.734 ± 0.094 a,b
Succinate1.763 ± 0.088 b6.00 ± 0.38 d26.769 ± 0.044 c3.10 ± 0.13 a2.451 ± 0.087 a,c
Trehalose105.0 ± 2.1 b318.7 ± 20.2 a281.6 ± 3.9 a270.7 ± 9.2 a347.7 ± 11.5 c
Tyrosine2.275 ± 0.052 b,c2.15 ± 0.14 b2.531 ± 0.088 c2.967 ± 0.079 a1.700 ± 0.044 b
The a–d within a column means that significance was determined by one-way ANOVA followed by post-hoc Tukey test (p < 0.01).
Table
Table 4. Content of glucans in Pleurotus mushroom extracts.
Table 4. Content of glucans in Pleurotus mushroom extracts.
Sample NameContent (% w/w of d.w.)
Total Glucansα-Glucansβ-Glucans
P. flabellatus 501335.8 ± 0.3 a4.5 ± 0.4 a31.5 ± 0.6 a
P. pulmonarius KZ5041.4 ± 0.1 b6.5 ± 0.8 ab34.9 ± 0.9 a
P. opuntiae 501244.4 ± 0.3 c9.8 ± 0.1 b34.5 ± 0.5 a
P. ostreatus Sylvan Ivory36.5 ± 0.1 a3.8 ± 1.2 a32.6 ± 1.2 a
P. ostreatus 5175 Florida49.0 ± 0.3 d5.6 ± 0.8 ab43.3 ± 0.6 b
The a–d within a column means that significance was determined by one-way ANOVA followed by post-hoc Tukey test (p < 0.01). The highest values in bold.
Table
Table 5. Antioxidant activities of 80% MeOH extracts of Pleurotus species sample extracts dissolved in DMSO.
Table 5. Antioxidant activities of 80% MeOH extracts of Pleurotus species sample extracts dissolved in DMSO.
Sample NameDPPHORACCAA Value
IC50 (μg/mL)mg of TE/(g Extract)mg of TE/(g Extract)% of NC
P. flabellatus 5013204.5 ± 45.8 a24.9 ± 5.4 a63.9 ± 4.0 d−1.7 ± 11.3 a
P. pulmonarius KZ50570.9 ± 97.4 b8.5 ± 1.3 b35.4 ± 2.2 a5.9 ± 11.8 a
P. opuntiae 5012390.6 ± 142.7 a,b13.5 ± 4.6 a,b36.2 ± 2.4 a6.6 ± 7.5 a
P. ostreatus Sylvan Ivory552.3 ± 119.0 a,b9.0 ± 1.8 a,b44.5 ± 4.5 cn.d.
P. ostreatus 5175 Florida 1134.0 ± 65.8 c4.3 ± 0.3 c21.7 ± 4.2 b6.6 ± 10.29 a
Quercetin (PC)---93.1 ± 4.4
80% MeOH (NC)−1.7 ± 14.2
The DPPH and ORAC results are expressed as means ± SD for four independent experiments measured in triplicate, while the CAA assay results are given as means ± SE for four independent experiments measured in triplicate. Abbreviations: n.d. = not determined; TE = Trolox equivalent. Values representing the highest activity in bold. The a–d within a column means that significance was determined by one-way ANOVA followed by post-hoc Tukey test (p < 0.01).
Table
Table 6. Anti-inflammatory activity of 80% MeOH and CHL extracts of Pleurotus spp. The protective effect was determined by measuring the extract’s ability to inhibit COX-2 and NF-κB/AP-1 activity.
Table 6. Anti-inflammatory activity of 80% MeOH and CHL extracts of Pleurotus spp. The protective effect was determined by measuring the extract’s ability to inhibit COX-2 and NF-κB/AP-1 activity.
Sample Name* COX-2 Average Inhibition ± SD (%)** NF-κB/AP-1 Activity ± SD (% of NC)
80% MeOHCHL80% MeOH
P. flabellatus 501328.4 ± 9.4 85.0 ± 0.8 a83.4 ± 18.4 a
P. pulmonarius KZ50not active55.6 ± 2.7 a,b76.6 ± 6.7 a
P. opuntiae 50122.4 ± 3.743.6 ± 12.9 b80.5 ± 18.6 a
P. ostreatus Sylvan Ivory24.0 ± 6.752.8 ± 8.7 a,bn.d.
P. ostreatus 5175 Floridanot active82.2 ± 2.7 a72.2 ± 7.7 a
20 μM ibuprofen (PC)79.0 ± 10.9 -
Prednisone (PC)-79.2 ± 8.0 a
80% MeOH (NC)100.0 ± 12.2 b
The results are expressed as means ± SD for three (*) or four (**) independent experiments measured in triplicate. Abbreviations: n.d. = not determined. The a,b within a column indicates significance as determined by one-way ANOVA followed by post-hoc Tukey test (p < 0.01).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Stastny, J.; Marsik, P.; Tauchen, J.; Bozik, M.; Mascellani, A.; Havlik, J.; Landa, P.; Jablonsky, I.; Treml, J.; Herczogova, P.; et al. Antioxidant and Anti-Inflammatory Activity of Five Medicinal Mushrooms of the Genus Pleurotus. Antioxidants 2022, 11, 1569. https://doi.org/10.3390/antiox11081569

AMA Style

Stastny J, Marsik P, Tauchen J, Bozik M, Mascellani A, Havlik J, Landa P, Jablonsky I, Treml J, Herczogova P, et al. Antioxidant and Anti-Inflammatory Activity of Five Medicinal Mushrooms of the Genus Pleurotus. Antioxidants. 2022; 11(8):1569. https://doi.org/10.3390/antiox11081569

Chicago/Turabian Style

Stastny, Jan, Petr Marsik, Jan Tauchen, Matej Bozik, Anna Mascellani, Jaroslav Havlik, Premysl Landa, Ivan Jablonsky, Jakub Treml, Petra Herczogova, and et al. 2022. "Antioxidant and Anti-Inflammatory Activity of Five Medicinal Mushrooms of the Genus Pleurotus" Antioxidants 11, no. 8: 1569. https://doi.org/10.3390/antiox11081569

APA Style

Stastny, J., Marsik, P., Tauchen, J., Bozik, M., Mascellani, A., Havlik, J., Landa, P., Jablonsky, I., Treml, J., Herczogova, P., Bleha, R., Synytsya, A., & Kloucek, P. (2022). Antioxidant and Anti-Inflammatory Activity of Five Medicinal Mushrooms of the Genus Pleurotus. Antioxidants, 11(8), 1569. https://doi.org/10.3390/antiox11081569

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop